Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
7.7
6x
60%
—
75.61%
Every year
—
5 Years
Score7.7
Net Growth6x
Net Trend60%
Net Income Consistency—
Rev Growth75.61%
Rev TrendEvery year
Revenue Consistency—
Biomarin Pharmaceutical Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 1.86B to $ 3.22B and net income declined from $ 854M to $ 348M. Revenue increased in every one of those 5 years; net income in 3.
Between 2005 and 2025, revenue grew from $ 25M to $ 3.22B and net income went from -$ 74M to $ 348M. Revenue increased in 19 of those 20 years; net income in 11.
Biomarin Pharmaceutical Inc currently holds a 20-year HDB Score of 6.0 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 70.24 | — |
1 Year2025-08-12 | $ 56.86 | 23.53% |
5 Years2021-08-12 | $ 75.39 | -6.83% |
10 Years2016-08-12 | $ 92.44 | -24.02% |
20 Years2006-08-11 | $ 15.08 | 365.78% |
All Time1999-07-23 | $ 13.13 | 435.16% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | All Time1999-07-23 |
|---|---|---|---|---|---|---|
| Price | $ 70.24 | $ 56.86 | $ 75.39 | $ 92.44 | $ 15.08 | $ 13.13 |
| Return | — | 23.53% | -6.83% | -24.02% | 365.78% | 435.16% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 3.24B | $ 268M | $ 2.22B |
| 2025 | $ 3.22B | $ 348M | $ 1.56B |
| 2024 | $ 2.85B | $ 426M | $ 1.13B |
| 2023 | $ 2.41B | $ 167M | $ 1.07B |
| 2022 | $ 2.09B | $ 141M | $ 1.29B |
| 2021 | $ 1.84B | -$ 64M | $ 1.01B |
| 2020 | $ 1.86B | $ 854M | $ 1.06B |
| 2019 | $ 1.70B | -$ 23M | $ 753M |
| 2018 | $ 1.49B | -$ 77M | $ 1.08B |
| 2017 | $ 1.31B | -$ 117M | $ 1.39B |
| 2016 | $ 1.11B | -$ 630M | $ 789M |
| 2015 | $ 889M | -$ 171M | $ 592M |
| 2014 | $ 749M | -$ 133M | $ 945M |
| 2013 | $ 548M | -$ 176M | $ 784M |
| 2012 | $ 500M | -$ 114M | $ 450M |
| 2011 | $ 441M | -$ 53M | $ 195M |
| 2010 | $ 376M | $ 205M | $ 274M |
| 2009 | $ 324M | -$ 488K | $ 300M |
| 2008 | $ 296M | $ 30M | $ 559M |
| 2007 | $ 121M | -$ 15M | $ 585M |
| 2006 | $ 84M | -$ 28M | $ 288M |
| 2005 | $ 25M | -$ 74M | $ 47M |
| 2004 | $ 18M | -$ 187M | $ 48M |
| 2003 | $ 12M | -$ 75M | $ 206M |
| 2002 | $ 13M | -$ 77M | $ 73M |
| 2001 | $ 11M | -$ 67M | $ 131M |
| 2000 | $ 9M | -$ 37M | $ 40M |
| IPO1999 | $ 5M | -$ 28M | $ 62M |
Explore beyond BMRN
You're looking at Biomarin Pharmaceutical Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
